



Published in final edited form as:

*Curr Opin Hematol.* 2017 January ; 24(1): 66–71. doi:10.1097/MOH.0000000000000303.

## Consequences of Extracellular Trap Formation in Sepsis

Xian M. O'Brien, Bethany M. Biron, and Jonathan S. Reichner

Department of Surgery, Rhode Island Hospital and the Warren Alpert Medical School at Brown University, Providence, RI 02903

### Abstract

**Purpose of Review**—This review will focus on *in vivo* findings derived from animal models of sepsis regarding the trapping role of NETs which is difficult to assess *ex vivo*. The NETotic response of neutrophils at sites of sterile injury or autoimmune disease is destructive as no antimicrobial advantage to the host is realized and dampening NETosis is largely beneficial. In early stages of local infection or in sepsis, the trapping function of NETs may help abscess formation and limit microbial dissemination.

**Recent Findings**—The trapping function of NETs limits bacterial dissemination keeping an abscess from becoming bacteremic or confining tissue infection to local sites. Once containment is lost and disease has progressed, the best therapeutic approach suggested by animal studies to date is to inhibit PAD4 and prevent NETosis rather than attempting to neutralize caustic NET components. Prognostic value may best be realized by taking cell free DNA, citrullinated histones, neutrophil function and counts of immature granulocytes into consideration rather than rely on any one measure alone.

**Summary**—The trapping function of NETs may supercede the value of antimicrobial function in the early phases of sepsis such that degradation of the DNA backbone is contraindicated.

### Keywords

NETs; Sepsis; Neutrophils

### Introduction

Sepsis is currently defined in 2016 as “*life-threatening organ dysfunction caused by a dysregulated host response to infection*” [1,2\*\*]. This updated definition was put forth by a task force of specialists convened by the Society of Critical Care Medicine and the European Society of Intensive Care Medicine. A clinical scoring system for organ dysfunction is newly provided (Sequential Sepsis-related Organ Failure Assessment; SOFA) allowing for more uniformity in assessment of the septic patient. A clinical distinction is now drawn between sepsis and septic shock wherein septic shock denotes a subset of septic patients

---

Corresponding Author: Jonathan S. Reichner, Department of Surgery, Rhode Island Hospital, 593 Eddy St., Providence, RI 02903. reichner@brown.edu. Phone: 401-444-8683.

### Conflicts of interest

The authors have no conflicts of interest.

with underlying hemodynamic alterations together with cellular/metabolic abnormalities that contribute significantly to mortality.

Sepsis is the leading cause of death of hospitalized patients worldwide [3]. A syndrome of physiologic, pathologic, and biochemical abnormalities induced by infection, sepsis becomes life-threatening when the inflammatory response to the infection persists without resolution and tissue damage progresses to multiple organ failure [2\*\*]. Later stages may include immune suppression and dysfunction [4]. However, there is currently no available FDA-approved treatment and the continued disappointment in devising effective treatments for sepsis was described in a commentary by Derek Angus entitled “*The search for effective therapy for sepsis: Back to the drawing board?*” [5]. In sepsis, neutrophils become systemically dysregulated and mediate much of the morbidity and mortality associated with the disease [6]. The clinical Holy Grail would be to gain iatrogenic fine control of neutrophil functions by dampening tissue destruction while maintaining full antimicrobial capacity.

## Initiation of NETosis

NETosis is a neutrophil effector mechanism in which cells extrude a mesh of chromatin fibers complexed with granule-derived antimicrobial peptides and enzymes [7\*\*]. NETs both physically contain microbes within the chromatin network and exert extracellular microbiocidal activity by associated granular enzymes.

NETosis is initiated by activation of Protein arginine deiminase 4 (PAD4) which postrationally deiminates histone arginine to citrulline. This neutralization of histone positive charge allows for relaxation of bound chromatin. Progression to NETosis includes chromatin decondensation, nuclear translocation of elastase, nuclear envelope disintegration, formation of an intracellular vacuole mixing DNA and granular contents, followed by extrusion through the plasma membrane. The kinetics of “classical” NETosis are slow, lagging hours post-stimulation, require reactive oxygen species (ROS), and culminate in a non-viable cell [8\*\*]. Rapid “vital” NETosis occurs within minutes of stimulation, independent of ROS, and likely leaves a viable enucleated cell still capable of migration and phagocytosis [9\*\*]. Whether NETosis proceeds *via* the “classical” or “vital” path may be a consequence of the ligand inducing the response as well as environmental factors including the presence of extracellular matrix [10,11,8\*\*]. Temporal differences are not likely due to the need for *de novo* gene expression [12]. Given that sepsis is most often polymicrobial with opsonized and non-opsonized microbial ligands proffered to a broad repertoire of neutrophil surface receptors, it is likely that all modes of NETosis are operative within the septic patient.

NETs are “traps” because their physical sequestering function prevents microorganism dissemination. Recently, *in vivo* imaging has provided insight into the containment function of NETs, which may prove to be its essential value in septic host defense. This containment comes at the expense of significant tissue damage, the balance of which must be weighed when considering NETosis as a therapeutic target in the septic patient.

## Animal Models of NETs in Sepsis and Systemic Inflammation

Although NETs have been shown to have microbiocidal or microbiostatic activity *in vitro*, DNase release of ensnared microbes was shown to leave these organisms in a viable state [13]. Whereas NET effects on microbial viability and proliferation are amenable to quantification *in vitro*, whether NETosis is a critical component of anti-microbial host defense and important in limiting microbial burden *in vivo* is less straightforward. This section summarizes lessons learned from murine models of infection, sepsis, and endotoxemia regarding the role of NETs [14\*\*–25] (Table 1). No one animal model can recapitulate clinical outcome exhibited by septic patients with variance in predisposing conditions and in disease etiology, severity and progression. The reader is referred to an outstanding review of the essentiality of continued, but wiser, use of murine models, in efforts to understand the biology of critical illness and to identify new therapeutic modalities relevant to human disease [26\*].

### NETs and Sepsis: When and how to intervene

The following section will describe findings derived from the application of animal models such as cecal ligation and puncture (CLP), bacterial installation or infusion, or the reductionist endotoxemia model has offered insight into the NETotic contribution to the pathobiology of infection and sepsis. As with any novel mechanism underlying a disease with no adequate therapy, NETs present a target for septic treatment. However, animal studies caution that the type and timing of intervention be carefully considered based on the stage of the disease. Therapeutic interventions may be proposed at the level of: (1) inhibiting NETosis; (2) dissociating the DNA meshwork; or (3) neutralization of caustic NET components such as elastase and histones [27\*]. Evidence suggests that the beneficial role of NETs as a means to contain microbial dissemination is best realized in localized infections, such as abscess formation or early trapping in the vasculature [9\*\*]. In early infection, NETosis may contribute to microbial sequestration thereby keeping the disease from becoming systemic. At this stage, DNase disruption of NETs would be contraindicated. Once containment is overwhelmed, or the patient responds with a systemic inflammatory response, then intervention may be aimed at neutralizing tissue damaging components of NETs. Moreover, inhibiting NETosis at advanced stages such as with PAD4 inhibitors might prove even more advantageous. Reductionist models of sepsis such as endotoxemia have shown a protective advantage in either the prevention of NETosis or the dissolution of intravascular NETs. Microbiocidal function of NETs does not seem to be a hallmark of host protection during sepsis *in vivo* [7\*\*].

### Bacterial Containment

*Staphylococcus aureus*, among the most common causes of bacteremia worldwide [28], is a potent inducer of NETosis. Staph infections begin locally but have a propensity for dissemination [4]. Yipp *et al.*, discovered that treating a localized abscess with DNase increased bacteremia and diminished skin bacterial content, suggesting that disrupting the NET structure compromises microbial containment [9\*\*].

Neutrophils accumulate within the microcirculation of vascularized tissues during sepsis [29]. In mice challenged with endotoxin or *Escherichia coli*, NETosis is induced in liver sinusoids through a novel mechanism that includes the bridging of activated platelets with neutrophils via LFA-1 as associated with significant liver damage [14\*\*]. *E. coli*-infected animals had significant bacterial trapping in sinusoid NETs. Similar to the abscess model, infusion of DNase disrupted these NET structures, releasing sequestered microbes into the bloodstream and the lung. *S. aureus* or viral infection of the liver caused similar pathology suggesting that this is a broad spectrum mechanism of host defense [14\*\*].

The production of the PAD4 knockout (ko) mouse by the laboratories of Wang and Mowen offered an important tool for *in vivo* experimental design directed at the enzyme with the best association with NETosis currently known. Neutrophils from PAD4ko mice are impaired in NETosis in response to proinflammatory agents including LPS, PMA, and H<sub>2</sub>O<sub>2</sub> [30,31]. *Shigella flexneri* was used to additionally characterize these PAD4ko mice as unable to elaborate NETs to an intact microbe and with significantly impaired extracellular killing [30]. Phagocytosis was similar to wild-type animals demonstrating no impairment by PAD4ko. Therefore these mice are the best tool currently available to interrogate the role of NETosis *in vivo* [23,19,32\*\*].

In a liver sinusoid NETosis model, mice injected with a sublethal dose of methicillin-resistant *Staphylococcus aureus* (MRSA) produced pronounced liver infection and tissue damage [32\*\*]. DNase treatment removed extracellular DNA in the infected liver but did not reduce tissue damage because histones and proteolytically-active elastase persisted even though clearance of bacteria was maintained. In contrast, NETosis and associated liver damage was greatly reduced in PAD4ko mice. This supports an organ dysfunction etiology that is not a consequence of the organism *per se*, but a result of collateral tissue injury. It remains to be determined if redundant antimicrobial effector mechanisms allow control of sublethal, low level infection, while the trapping and antimicrobial function of NETs gain heightened significance when the infectious challenge is of greater magnitude.

Neutrophil evasion is a microbial virulence mechanism employed by Group A *Streptococcus* (GAS) M1 in secreting streptodornase D (Sda1), an extracellular DNase that can degrade NETs. Indeed, Sda1 expression degraded NETs from wild-type PMNs, reducing microbial killing to that of PAD4ko neutrophils [33]. Depletion of Sda1 removed this virulence mechanism and restored *Streptococcus* killing in wild-type neutrophils. In a subcutaneous GAS Sda1 injection model of necrotizing fasciitis, PAD4ko mice were significantly more susceptible to infection with larger lesions containing more viable bacteria, likely due impaired NETosis.

Therefore, using both skin abscess and liver sinusoid models of infection, the Kubers lab showed bacterial trapping and containment by NETs and dissemination when NETs were disrupted. These studies support bacterial entrapment rather than bacterial destruction as the primary NET function in infection. That PAD4ko mice were also shown to be highly susceptible to skin infections such as necrotizing fasciitis demonstrates that NETosis is also fundamental to the surveillance function of the immune system limiting colonization by normal flora [33]. Neutrophils possess numerous bacteriocidal mechanisms and NETs may

contribute to killing efficiency to some extent but may be redundant -cidal means as compared to the unique mode of trapping offered by NETs [34,33].

## Cecal Ligation and Puncture

To determine the role of PAD4 in protection from polymicrobial sepsis, wild-type and PAD4ko mice were subject to CLP [19]. The absence of PAD4 had no effect on either survival or bacteremia in a low-grade infection model with 20% mortality, albeit with a narrow observation window. More compellingly, PAD4ko mice showed no survival difference in a high-grade infection, inducing 80% mortality. However, a slight survival benefit was reported in wild-type compared to PAD4ko when exposed to high-grade CLP with antibiotic treatment; bacteremia was not affected. Cl-aminidine, a pharmacological inhibitor of PAD activity, was shown to improve survival in a CLP model with 50% mortality [35].

Repeated delivery of DNase into the peritoneal cavity in a CLP model with 80% mortality showed a transient increase in mortality at 24h but no overall survival difference [24]. This supports the trapping utility of NETs early in the course of disease by limiting dissemination. Another report using a severe model of CLP that resulted in 100% mortality by 48hr, DNase did not improve long-term survival [15]. A minor survival benefit was seen with antibiotic treatment, however, a significant (50%) survival benefit and improved organ function was seen in animals receiving both antibiotic and DNase, in combination. Administration of DNase to animals receiving LPS as a model of endotoxemia had a notable survival advantage with diminished organ pathology. These data using endotoxemia or antibiotic support to minimize the impact of NET sequestration highlight the deleterious effects of NETs in disease progression.

An interesting consideration regarding the use of the CLP model to understand the role of NETs in sepsis was raised by Sørensen and Borregaard [7\*\*] who questioned whether the serosal surface of the peritoneum is sufficient to allow adherence of NETs and, in turn, containment of bacteria. In this regard, the peritoneal cavity has not as yet been shown to support NET immobilization. Therefore, findings to date merit cautious interpretation.

Histones released as a component of extracellular chromatin are directly toxic to endothelial cells and contribute to vascular dysfunction, organ injury, and death in sepsis [25]. Anti-histone antibodies protected mice from mortality following TNF, LPS, or CLP challenge [23,25]. Administration of purified histones to naïve animals mimicked many hyperinflammatory hallmarks of sepsis including neutrophil margination, damaged endothelium, intra-alveolar hemorrhage, and thrombosis. Subsequently, histones were shown to activate platelets and inhibit activation of protein C leading to thrombosis [36].

Another study using the CLP model showed a survival benefit after infusion of anti-histone H4 antibody but, as in the case of DNase therapy, survival was only improved with antibody was given together with antibiotic [25]. Using LPS infusion at a dose to cause 80% mortality, anti-H4 antibody reduced mortality to 20%. It may be of significance in terms of therapeutic design that in order for the antibody to be most effective, a 6 hour delay of

treatment with both antibiotic and anti-histone antibody relative to CLP was incorporated into the treatment protocol, perhaps because of the antimicrobial functions of histones in innate immunity. No such delay was needed in the LPS model to observe a survival benefit [25]. The excitement raised by these studies identified extracellular histones as a therapeutic target in sepsis and other hyperinflammatory diseases. However, removal of NETs by DNase, or neutralization of histones, did not protect the liver vasculature as effectively as prevention of NETosis as in PAD4 or Elastase knockout mice [32\*\*]. This work offers experimental evidence for the therapeutic advantage of preventing NETosis rather than dissociating or blocking tissue-damaging components of NETs after exocytosis.

## Intervention and Prognostic Opportunities

Interventional strategies to block NETosis would be counterproductive if they caused overt immune suppression or subverted other neutrophil effector functions during a case of active sepsis, particularly in the case of sepsis where infection is pathognomic of the disease. Therefore, an “Ideal” NET inhibitor should prevent trap release but preserve other antimicrobial effector functions [37]. Therapeutic approaches regarding specific attenuation of NETosis during sepsis includes: 1. Infusion of anti-citrullinated antibodies [25,38], 2. blocking platelet:PMN interactions *via* the peptide MKEY and anti-Mac1 antibodies [39]; 3. An interesting approach towards preventing NETosis while preserving neutrophil function is the finding of Van Avondt *et al.* that cross-linking the signal inhibitory receptor on leukocytes-1 (SIRL-1) obviating NET release from opsonized as well as nonopsonized *S. aureus* [40]. Additionally, indirect targets such as Peroxisome proliferator-activated receptor gamma (PPAR $\gamma$ ) and Phospholipase D2 (PLD2) with modulating effects on NETosis have been considered [16,17]. Temporally appropriate inhibition of NET release may be therapeutically more efficient than attempts to neutralize histones, DNA or other NET components after the cat is out of the bag.

A consequence of a NETotic response is the increased levels of circulating cell free DNA and citrullinated histones which have been pursued for their potential as a clinical biomarker of illness severity and progression [41]. In a retrospective observational study of 80 septic patients, one study showed the cfDNA levels were predictive of intensive care mortality [42]. Further refinements in the technology of objectively quantifying blood cells for evidence of NETosis are ongoing [43]. However, a recent longitudinal study of interest has shown that combined measures of cf-DNA, plasma citrullinated histones, phagocytic capacity of blood neutrophils and number of immature granulocytes, when considered together, was predictive of the development of sepsis in patients as early as one day following severe burn injury [44\*\*].

## Conclusion

Physical entrapment within NETs prior to and during sepsis is the predominant beneficial effector mechanism offered by this pathway whereas the contribution of NETosis to microbial killing may be dispensable or redundant with other effector pathways such as phagocytosis and oxidant production. The preponderance of evidence in this regard has been provided by the laboratory of Paul Kubers and collaborators who have maximized the use of

dual laser multichannel spinning-disk confocal microscopy to provide real time *in vivo* evidence of neutrophil function within viable tissues. As such his laboratory has generated a prodigious body of convincing and paradigm-generating data regarding into the host response to injury and infection and much may be extrapolated to the role of NETosis during sepsis. Until a naturally occurring human mutation in PAD4 is identified, it will be difficult to know with certainty the extent to which NETosis is dispensable or redundant in human health.

## Acknowledgments

The authors thank Dr. Sean Monaghan for helpful discussions.

### Financial support and sponsorship

This work was supported by the United States National Institutes of Health grant GM066194 (JSR) and funds from the Department of Surgery, Rhode Island Hospital.

Funding: NIH GM066194 (JSR)

## References

1. Vincent J-L, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. *Lancet* (London, England). 2013; 381:774–5.
- 2\*\*. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche J-D, Cooper-Smith CM, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016; 315:801–10. *This report communicates a significant update in definitions and clinical criteria of sepsis.* [PubMed: 26903338]
3. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. *Virulence*. 2014; 5:4–11. [PubMed: 24335434]
4. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. *Nat Rev Immunol*. 2013; 13:862–74. [PubMed: 24232462]
5. Angus DC. The search for effective therapy for sepsis: back to the drawing board? *JAMA*. 2011; 306:2614–5. [PubMed: 22187284]
6. Kovach MA, Standiford TJ. The function of neutrophils in sepsis. *Curr Opin Infect Dis*. 2012; 25:321–7. [PubMed: 22421753]
- 7\*\*. Sørensen OE, Borregaard N. Neutrophil extracellular traps - the dark side of neutrophils. *J Clin Invest*. 2016; 126:1612–20. *An outstanding critical review of NET formation and their role in infectious and autoimmune disease.* [PubMed: 27135878]
- 8\*\*. Yipp BG, Kubes P. NETosis: how vital is it? *Blood*. 2013; 122:2784–94. *An excellent review of the pathways leading to suicidal or vital NETosis.* [PubMed: 24009232]
- 9\*\*. Yipp BG, Petri B, Salina D, Jenne CN, Scott BNV, Zbytniuk LD, Pittman K, Asaduzzaman M, Wu K, Meijndert HC, et al. Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo. *Nat Med*. 2012; 18:1386–93. *This study is the first demonstration of viable NETosis and compelling in vivo evidence that disruption of NETs leads to loss of containment.* [PubMed: 22922410]
10. Parker H, Dragunow M, Hampton MB, Kettle AJ, Winterbourn CC. Requirements for NADPH oxidase and myeloperoxidase in neutrophil extracellular trap formation differ depending on the stimulus. *J Leukoc Biol*. 2012; 92:841–9. [PubMed: 22802447]
11. Kaplan MJ, Radic M. Neutrophil extracellular traps: double-edged swords of innate immunity. *J Immunol*. 2012; 189:2689–95. [PubMed: 22956760]
12. Sollberger G, Amulic B, Zychlinsky A, Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A, Mocsai A, Brinkmann V, et al. Neutrophil Extracellular Trap Formation Is Independent of De Novo Gene Expression. *PLoS One*. 2016; 11:e0157454. [PubMed: 27310721]

13. Menegazzi R, Decleva E, Dri P. Killing by neutrophil extracellular traps: fact or folklore? *Blood*. 2012; 119:1214–6. [PubMed: 22210873]
- 14\*\*. McDonald B, Urrutia R, Yipp BG, Jenne CN, Kubes P. Intravascular Neutrophil Extracellular Traps Capture Bacteria from the Bloodstream during Sepsis. *Cell Host Microbe*. 2012; 12:324–333. *This study presents evidence of in vivo trapping by NETs in the liver sinusoids via a mechanism of platelet-neutrophil interactions.* [PubMed: 22980329]
15. Czaikoski PG, Mota JMSC, Nascimento DC, Sónego F. Neutrophil Extracellular Traps Induce Organ Damage during Experimental and Clinical Sepsis. *PLoS One*. 2016; 11:e0148142. [PubMed: 26849138]
16. Araújo CV, Campbell C, Gonçalves-de-Albuquerque CF, Molinaro R, Cody MJ, Yost CC, Bozza PT, Zimmerman GA, Weyrich AS, Castro-Faria-Neto HC, et al. A PPAR $\gamma$  AGONIST ENHANCES BACTERIAL CLEARANCE THROUGH NEUTROPHIL EXTRACELLULAR TRAP FORMATION AND IMPROVES SURVIVAL IN SEPSIS. *Shock*. 2016; 45:393–403. [PubMed: 26618986]
17. Lee SK, Kim SD, Kook M, Lee HY, Ghim J, Choi Y, Zabel BA, Ryu SH, Bae Y-S. Phospholipase D2 drives mortality in sepsis by inhibiting neutrophil extracellular trap formation and down-regulating CXCR2. *J Exp Med*. 2015; 212:1381–90. [PubMed: 26282875]
18. Mai SHC, Khan M, Dwivedi DJ, Ross CA, Zhou J, Gould TJ, Gross PL, Weitz JI, Fox-Robichaud AE, Liaw PC, et al. Delayed but not Early Treatment with DNase Reduces Organ Damage and Improves Outcome in a Murine Model of Sepsis. *Shock*. 2015; 44:166–72. [PubMed: 26009820]
19. Martinod K, Fuchs TA, Zitomersky NL, Wong SL, Demers M, Gallant M, Wang Y, Wagner DD. PAD4-deficiency does not affect bacteremia in polymicrobial sepsis and ameliorates endotoxemic shock. *Blood*. 2015; doi: 10.1182/blood-2014-07-587709
20. Wildhagen KCAA, García de Frutos P, Reutelingsperger CP, Schrijver R, Aresté C, Ortega-Gómez A, Deckers NM, Hemker HC, Soehnlein O, Nicolaes GAF. Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis. *Blood*. 2014; 123:1098–101. [PubMed: 24264231]
21. Luo L, Zhang S, Wang Y, Rahman M, Syk I, Zhang E, Thorlacius H. Proinflammatory role of neutrophil extracellular traps in abdominal sepsis. *Am J Physiol Lung Cell Mol Physiol*. 2014; 307:L586–96. [PubMed: 25085626]
22. de Jong HK, Koh GC, Achouiti A, van der Meer AJ, Bulder I, Stephan F, Roelofs JJ, Day NP, Peacock SJ, Zeerleder S, et al. Neutrophil extracellular traps in the host defense against sepsis induced by *Burkholderia pseudomallei* (melioidosis). *Intensive care Med Exp*. 2014; 2:21. [PubMed: 26215706]
23. Li Y, Liu Z, Liu B, Zhao T, Chong W, Wang Y, Alam HB. Citrullinated histone H3: A novel target for the treatment of sepsis. *Surgery*. 2014; 156:229–234. [PubMed: 24957671]
24. Meng W, Paunel-Görgülü A, Flohé S, Hoffmann A, Witte I, MacKenzie C, Baldus SE, Windolf J, Lögters TT. Depletion of neutrophil extracellular traps in vivo results in hypersusceptibility to polymicrobial sepsis in mice. *Crit Care*. 2012; 16:R137. [PubMed: 22835277]
25. Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, Taylor FB, Esmon NL, Lupu F, Esmon CT. Extracellular histones are major mediators of death in sepsis. *Nat Med*. 2009; 15:1318–21. [PubMed: 19855397]
- 26\*. Osuchowski MF, Remick DG, Lederer JA, Lang CH, Aasen AO, Aibiki M, Azevedo LC, Bahrami S, Boros M, Cooney R, et al. Abandon the mouse research ship? Not just yet! *Shock*. 2014; 41:463–75. *A well balanced overview of the use of mouse models in the critical care medicine.* [PubMed: 24569509]
- 27\*. Liu F-C, Chuang Y-H, Tsai Y-F, Yu H-P. Role of neutrophil extracellular traps following injury. *Shock*. 2014; 41:491–8. *A summation of therapeutic target opportunities in NETosis.* [PubMed: 24837201]
28. Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, Kirby A, Tilley R, Török ME, Walker S, Wertheim HF, Wilson P, Llewelyn MJ. Clinical management of *Staphylococcus aureus* bacteraemia. *Lancet Infect Dis*. 2011; 11:208–222. [PubMed: 21371655]
29. Brown K, Brain S, Pearson J, Edgeworth J, Lewis S, Treacher D. Neutrophils in development of multiple organ failure in sepsis. *Lancet*. 2006; 368:157–169. [PubMed: 16829300]



30. Li P, Li M, Lindberg MR, Kennett MJ, Xiong N, Wang Y. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. *J Exp Med*. 2010; 207:1853–62. [PubMed: 20733033]
31. Hemmers S, Teijaro JR, Arandjelovic S, Mowen KA. PAD4-mediated neutrophil extracellular trap formation is not required for immunity against influenza infection. *PLoS One*. 2011; 6:e22043. [PubMed: 21779371]
- 32\*\*. Kolaczowska E, Jenne CN, Surewaard BGJ, Thanabalasuriar A, Lee W-Y, Sanz M-J, Mowen K, Opdenakker G, Kubes P. Molecular mechanisms of NET formation and degradation revealed by intravital imaging in the liver vasculature. *Nat Commun*. 2015; 6:6673. *Elegant demonstration that inhibiting NET formation via PAD4 or elastase knockout mice preserved tissue from NETotic damage better than dissolution or blocking of NET components*. [PubMed: 25809117]
33. Buchanan JT, Simpson AJ, Aziz RK, Liu GY, Kristian SA, Kotb M, Feramisco J, Nizet V. DNase Expression Allows the Pathogen Group A Streptococcus to Escape Killing in Neutrophil Extracellular Traps. 2006
34. Nauseef WM, Borregaard N. Neutrophils at work. *Nat Immunol*. 2014; 15:602–11. [PubMed: 24940954]
35. Biron BM, Chung C-S, O'Brien XM, Chen Y, Reichner JS, Ayala A. Cl-amidine prevents histone 3 citrullination, NET formation, and improves survival in a murine sepsis model. *J Innate Immun*. 2016 [no volume].
36. Fuchs TA, Bhandari AA, Wagner DD. Histones induce rapid and profound thrombocytopenia in mice. *Blood*. 2011; 118:3708–14. [PubMed: 21700775]
37. Yost CC. Toward the “ideal” inhibitor of NETs. *Blood*. 2014; 123:2439–40. [PubMed: 24744245]
38. Xu Z, Huang Y, Mao P, Zhang J, Li Y. Sepsis and ARDS: The Dark Side of Histones. *Mediators Inflamm*. 2015; 2015:205054. [PubMed: 26609197]
39. Rossaint J, Herter JM, Van Aken H, Napirei M, Döring Y, Weber C, Soehnlein O, Zarbock A. Synchronized integrin engagement and chemokine activation is crucial in neutrophil extracellular trap-mediated sterile inflammation. *Blood*. 2014; 123:2573–84. [PubMed: 24335230]
40. Van Avondt K, van der Linden M, Naccache PH, Egan DA, Meyaard L. Signal Inhibitory Receptor on Leukocytes-1 Limits the Formation of Neutrophil Extracellular Traps, but Preserves Intracellular Bacterial Killing. *J Immunol*. 2016; 196:3686–94. [PubMed: 27016607]
41. Hirose T, Hamaguchi S, Matsumoto N, Irisawa T, Seki M, Tasaki O, Hosotsubo H, Yamamoto N, Yamamoto K, Akeda Y, et al. Presence of neutrophil extracellular traps and citrullinated histone H3 in the bloodstream of critically ill patients. *PLoS One*. 2014; 9:e111755. [PubMed: 25392950]
42. Dwivedi DJ, Toltl LJ, Swystun LL, Pogue J, Liaw K-L, Weitz JI, Cook DJ, Fox-Robichaud AE, Liaw PC, Canadian Critical Care Translational Biology Group. Prognostic utility and characterization of cell-free DNA in patients with severe sepsis. *Crit Care*. 2012; 16:R151. [PubMed: 22889177]
43. Zhao W, Fogg DK, Kaplan MJ. A novel image-based quantitative method for the characterization of NETosis. *J Immunol Methods*. 2015; 423:104–110. [PubMed: 26003624]
- 44\*. Hampson P, Dinsdale RJ, Wearn CM, Bamford AL, Bishop JRB, Hazeldine J, Moiemens NS, Harrison P, Lord JM. Neutrophil Dysfunction, Immature Granulocytes, and Cell-free DNA are Early Biomarkers of Sepsis in Burn-injured Patients: A Prospective Observational Cohort Study. *Ann Surg*. 2016; The first longitudinal study showing peripheral blood neutrophil function and biomarkers of NETosis have prognostic value in sepsis in a cohort of severely burn injured patients. doi: 10.1097/SLA.0000000000001807

**Key Points**

- Updated definitions and clinical criteria of sepsis should replace prior definitions.
- Containment function of NETs is important during early phases of infection and may limit progression to sepsis and/or sepsis severity. Disruption of NET architecture at this stage should be avoided.
- Animal models of polymicrobial sepsis are only slightly affected by genetic absence of PAD4.
- When taken together, neutrophil function, cfDNA, citrullinated histones and number of immature granulocytes may have prognostic significance in identifying the likelihood of burn patients becoming septic.

**Table 1**

Effects of NET formation in mouse models of infection

| NET inhibition method                                   | Sepsis model   | Microbial burden   | Survival  | Reference                    |
|---|--|--|---|------------------------------|
| rh DNase  | CLP  | Increase - blood   | Decrease  | Czaikoski <i>et al.</i> [15] |
| rhDNase + antibiotic                                    | CLP  | Decrease - blood   | Increase  | Czaikoski <i>et al.</i> [15] |
| PPAR $\gamma$ agonist <sup>a</sup>                      | CLP  | Decrease - peritoneum  | Increase  | Araújo <i>et al.</i> [16]    |
| PLD2 <sup>-/-a</sup>                                    | CLP  | Decrease - blood, BALF, peritoneum, lung, spleen and liver   | Increase  | Lee <i>et al.</i> [17]       |
| DNase   | CLP  | Decrease - blood, peritoneum and lung <sup>b</sup>   | No difference - early treatment increase - late treatment | Mai <i>et al.</i> [18]       |
| PAD4 <sup>-/-</sup>                                     | CLP  | No change - blood, liver and lung  | No difference   | Martinod <i>et al.</i> [19]  |
| Antithrombin affinity depleted heparin                  | CLP  | ND   | Increase  | Wildhagen <i>et al.</i> [20] |
| DNase   | CLP  | Decrease - lung (6 h pCLP) Decrease - blood, lung and spleen (24 h pCLP)                                   | ND  | Luo <i>et al.</i> [21]       |
| DNase   | Intranasal administration <i>Borkholderia pseudomallei</i> | No difference - BALF, blood, lung and liver  | ND  | Jong <i>et al.</i> [22]      |
| H3cit inhibitors (Cl- amidine, anti-CitH3)              | CLP  | ND   | Increase - Cl-amidine Increase - anti-CitH3               | U <i>et al.</i> [23]         |
| rhDNase   | CLP  | Increase — peritoneum and lung (6 h pCLP) no difference - blood, lung, peritoneum and liver [24–40 h pCLP] | No difference <sup>c</sup>                                | Meng <i>et al.</i> [24]      |
| Platelet-depleting serum Dnase LFA1 <sup>-/-</sup> mice | IP injection <i>Escherichia coli</i>                       | Increase — blood and lung  | ND  | McDonald <i>et al.</i> [14]  |
| Anti-H4+antibiotic                                      | CLP  | ND   | Increase  | Xu <i>et al.</i> [25]        |

<sup>a</sup>Increases NET formation and enhances bacterial killing.

<sup>b</sup>Decreases seen in delayed DNase administration (4 and 6 h post CLP).

<sup>c</sup>Increased survival noticed 24 h post CLP that was abolished by 48 h post CLP.

BALF, bronchoalveolar lavage fluid; CLP, cecal ligation and puncture; LFA1, Lymphocyte function-associated antigen 1; ND, not determined; NET, neutrophil extracellular trap.